Skip to content

Advertisement

  • Poster presentation
  • Open Access

Trimethoprim sulfamethoxazole drug resistance with co resistance to extended spectrum β-lactam antibiotics among bacterial isolates from HIV patients

  • 1,
  • 1,
  • 2,
  • 2,
  • 2 and
  • 1Email author
BMC Infectious Diseases201414 (Suppl 3) :P57

https://doi.org/10.1186/1471-2334-14-S3-P57

  • Published:

Keywords

  • Cefotaxime
  • Ceftazidime
  • Trimethoprim
  • Klebsiella Pneumoniae
  • Sulfamethoxazole

Background

Trimethoprim-sulfamethoxazole (TMP-SMX) is a broad spectrum antimicrobial agent and also reduces the mortality among adults and children when used as prophylaxis against opportunistic infections in HIV infected patients. Drug resistant to TMP-SMX along with Extended spectrum β-lactamase (ESBL) production among Enterobacteriaceae is creating major therapeutic problem in clinical settings for treating the bacterial infections among HIV individuals.

Methods

TMP-SMX drug resistance among the isolates was identified using Kirby-Bauer disc diffusion method and ESBL production by combination disc method (CDM). Cefotaxime (30µg) and cefotaxime/clavulanic acid (30μg/10μg) discs were placed 20 mm apart on the agar surface. Similarly, the ceftazidime (30µg) and ceftazidime/clavulanic acid (30μg/10μg) discs were also placed. After incubating overnight at 37°C, a ≥ 5mm increase in the zone diameter was interpreted as positive for ESBL production. Statistical analysis was done using SPSS software version 15.0.

Results

A total of 103(40 Escherichia coli, 15 Klebsiella pneumoniae, 13 Pseudomonas aeruginosa, 10 Klebsiella oxytoca, 8 Proteus mirabilis, 2 Proteus vulgaris, 11 Staphylococcus aureus, 3 Staphylococcus epidermidis and 1 Streptococcus sp.) bacterial strains were isolated from HIV patients. Among these 65(63.10%;p=0.008) isolates were resistance to TMP-SMX and only 40(38.83%;p=0.023) isolates were resistant to extended spectrum β-lactam antibiotics. Twenty nine ESBL producers from HIV patients were found to be co resistant to TMP-SMX. All ESBL producing isolates showed resistance to ceftazidime and also for ceftazidime/clavulanic acid combination.

Conclusion

A rapid increase in the use of prophylactic TMP-SMX might be responsible for the TMP-SMX drug resistance among opportunistic bacterial infections in HIV patients.

Authors’ Affiliations

(1)
PG & Research Department of Microbiology and Biotechnology, Presidency College (Autonomous), Chennai, India
(2)
YRG Centre for AIDS Research and Education, Chennai, India

Copyright

Advertisement